Events Partner Content 3rd Microbiome Movement – Maternal & Infant Health Summit Treatment creation for maternal and infant microbiome
Partner Content Partner Content Personal Highlights – Microbiome Movement – Maternal & I... Discovering The Maternal-Infant Microbiome
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.